Dr. Shubham Gupta on building a gender affirmation care program

“What is becoming increasingly evident is that the traditional health care model is falling short for patients in rural regions,” says Ramy Abou Ghayda, MD, MPH, MBA candidate.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

Data revealed that 49% of prostate cancer signups in clinical trials were among patients newly diagnosed with cancer, compared with 32% among patients with other solid tumors.

“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.